002412 汉森制药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)4.5158.64310.57210.6309.219
总资产报酬率 ROA (%)4.1517.5619.0208.8617.615
投入资产回报率 ROIC (%)4.4568.37410.10910.0288.595

边际利润分析
销售毛利率 (%)78.37177.36375.85573.22072.065
营业利润率 (%)25.67923.02225.20624.58720.609
息税前利润/营业总收入 (%)25.80823.04025.31923.85520.201
净利润/营业总收入 (%)22.38519.07321.92621.45618.297

收益指标分析
经营活动净收益/利润总额(%)81.84198.96291.74275.78571.639
价值变动净收益/利润总额(%)19.0253.4344.76627.85050.979
营业外收支净额/利润总额(%)0.429-0.223-0.169-3.947-3.815

偿债能力分析
流动比率 (X)14.7914.5843.5282.5212.276
速动比率 (X)12.0043.8612.8281.8711.627
资产负债率 (%)4.17811.59113.49915.98417.321
带息债务/全部投入资本 (%)-0.8511.4472.7364.1045.544
股东权益/带息债务 (%)-11,738.7946,744.4553,514.4592,315.2561,689.107
股东权益/负债合计 (%)2,293.647762.749640.793525.633477.337
利息保障倍数 (X)1,384.307330.946162.138118.65557.848

营运能力分析
应收账款周转天数 (天)110.04198.66897.90892.56186.375
存货周转天数 (天)375.231330.175336.946336.050246.182